MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-18-2023
Aptinyx Operating Income 2011-2026 | APTX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -62.6 M | -74.5 M | -50.8 M | -59.6 M | -54.9 M | -32.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -32.2 M | -74.5 M | -55.8 M |
Quarterly Operating Income Aptinyx
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.3 M | - | -14.7 M | - | -19.4 M | - | -21.2 M | -19.9 M | -14.3 M | - | -11.4 M | -12.6 M | -15.1 M | - | -15.3 M | -12.7 M | -17.3 M | - | -14.8 M | -13.6 M | -11.8 M | - | -8.18 M | -8.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.04 M | -21.2 M | -14.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M |  USA |
 |
Agenus
AGEN
|
-160 M | $ 3.27 | -1.8 % | $ 1.17 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-472 M | $ 29.33 | -2.98 % | $ 1.7 B | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.26 | -3.44 % | $ 324 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-21.6 M | $ 0.24 | 1.1 % | $ 5.73 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
-35.3 M | $ 5.49 | 0.52 % | $ 330 M | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alector
ALEC
|
-156 M | $ 2.26 | -7.2 % | $ 233 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Aligos Therapeutics
ALGS
|
-88.1 M | $ 7.02 | -0.21 % | $ 451 M | USA |
 |
Alkermes plc
ALKS
|
254 M | $ 29.32 | -2.61 % | $ 4.83 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-328 M | $ 2.57 | -7.73 % | $ 403 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 330.95 | -0.59 % | $ 43.4 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Altimmune
ALT
|
-103 M | $ 4.2 | -2.55 % | $ 298 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-142 M | $ 2.11 | 0.09 % | $ 110 M | USA |
 |
Amgen
AMGN
|
9.08 B | $ 387.85 | 0.03 % | $ 209 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 20.22 | -0.05 % | $ 945 M | USA |
 |
Amarin Corporation plc
AMRN
|
-67.6 M | $ 13.62 | -1.3 % | $ 5.55 B | Irlanda |
 |
AIM ImmunoTech
AIM
|
-19.9 M | $ 0.92 | 5.25 % | $ 44.2 M | USA |
 |
AnaptysBio
ANAB
|
-115 M | $ 54.61 | -0.8 % | $ 1.55 B | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.44 | 0.53 % | $ 212 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
584 K | $ 75.31 | 1.91 % | $ 1.45 B | USA |
 |
Annexon
ANNX
|
-154 M | $ 5.38 | -3.93 % | $ 739 M | USA |
 |
Annovis Bio
ANVS
|
-45 M | $ 2.6 | -2.99 % | $ 23.5 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.53 | -2.05 % | $ 2.59 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Aprea Therapeutics
APRE
|
-15.5 M | $ 0.88 | -3.71 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
-24.6 M | $ 7.28 | -0.55 % | $ 2.01 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aquestive Therapeutics
AQST
|
-30.8 M | $ 3.99 | -0.15 % | $ 346 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-95.7 M | $ 8.11 | -1.44 % | $ 219 M |  Israel |
 |
Ardelyx
ARDX
|
-41 M | $ 6.32 | -3.54 % | $ 1.52 B | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 762.51 | -0.58 % | $ 25 B |  Niderland |